MARKET

ACHFF

ACHFF

Arch Biopartners
OTCMQB
0.706
-0.091
-11.43%
Closed 15:48 08/20 EDT
OPEN
0.780
PREV CLOSE
0.797
HIGH
0.780
LOW
0.700
VOLUME
6.60K
TURNOVER
4.88K
52 WEEK HIGH
1.220
52 WEEK LOW
0.290
MARKET CAP
47.96M
P/E (TTM)
-25.1246
1D
5D
1M
3M
1Y
5Y
1D
Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States
Barchart · 08/11 06:44
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
Barchart · 06/04 06:41
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
Barchart · 05/22 05:50
Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD
TipRanks · 02/09 12:45
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Barchart · 02/09 06:28
Arch granted ethics approval for St. Michaels participation in Phase II trial
TipRanks · 12/16/2025 12:45
Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide
Barchart · 12/16/2025 06:40
Arch biopartners launches non-brokered private placement
Seeking Alpha · 11/10/2025 14:16
More
About ACHFF
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.

Webull offers Arch Biopartners Inc stock information, including OTCMQB: ACHFF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHFF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHFF stock methods without spending real money on the virtual paper trading platform.